HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $311,521 | +26.2% | 8,155 | +19.1% | 0.01% | +25.0% |
| Q2 2023 | $246,899 | -11.8% | 6,845 | -6.6% | 0.00% | 0.0% |
| Q1 2023 | $279,971 | -38.2% | 7,331 | -7.9% | 0.00% | -42.9% |
| Q4 2022 | $452,981 | -5.4% | 7,961 | -34.3% | 0.01% | -22.2% |
| Q3 2022 | $479,000 | -0.6% | 12,113 | +10.7% | 0.01% | 0.0% |
| Q2 2022 | $482,000 | +17.6% | 10,947 | +6.4% | 0.01% | +28.6% |
| Q1 2022 | $410,000 | -0.7% | 10,292 | +0.2% | 0.01% | 0.0% |
| Q4 2021 | $413,000 | -1.2% | 10,273 | +0.3% | 0.01% | -22.2% |
| Q3 2021 | $418,000 | +8.3% | 10,243 | +20.5% | 0.01% | +12.5% |
| Q2 2021 | $386,000 | +8.7% | 8,503 | -0.1% | 0.01% | 0.0% |
| Q1 2021 | $355,000 | -3.0% | 8,511 | -0.6% | 0.01% | -20.0% |
| Q4 2020 | $366,000 | +36500.0% | 8,561 | +34144.0% | 0.01% | – |
| Q3 2020 | $1,000 | 0.0% | 25 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 25 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |